Literature DB >> 8033090

Cell cycle arrests and radiosensitivity of human tumor cell lines: dependence on wild-type p53 for radiosensitivity.

A J McIlwrath1, P A Vasey, G M Ross, R Brown.   

Abstract

Loss of p53 function has been shown to cause increased resistance to ionizing radiation in normal murine cells; however, the role of p53 in radioresistance of human tumor cells is less clear. Since wild-type p53 function is required for radiation-induced G1 arrest, we measured G1 arrest in 12 human tumor cell lines that have a wide range of radiosensitivities (surviving fraction at 2 Gy, 0.11-0.8). We observed a significant correlation between the level of ionizing radiation-induced G1 arrest and radiosensitivity. Cell lines having G1 arrest are more radiosensitive. There is no correlation between maximal G2 arrest and radiosensitivity. Expression of a dominant-negative mutant of p53 (codon 143, Val to Ala) in transfectants of the radiosensitive human ovarian cell line A2780 abrogates the radiation-induced G1 arrest. Such mutant p53 transfectants are more resistant to ionizing radiation than the parental line and vector-alone transfectants, as measured by clonogenic assays. These results support the concept that wild-type p53 function is required for sensitivity of tumor cells to DNA-damaging agents, such as ionizing radiation, and that the loss of p53 function in certain human tumor cells can lead to resistance to ionizing radiation.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8033090

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  49 in total

Review 1.  Molecular Biology: Are We Getting Any Closer to Providing Clinically Useful Information?

Authors:  Georgios Karagkounis; Matthew F Kalady
Journal:  Clin Colon Rectal Surg       Date:  2017-11-27

2.  Human chromosome 3 mediates growth arrest and suppression of apoptosis in microcell hybrids.

Authors:  M D Speevak; M Chevrette
Journal:  Mol Cell Biol       Date:  1996-05       Impact factor: 4.272

3.  The biological effect of pentoxifylline on the survival of human head and neck cancer cells treated with continuous low and high dose-rate irradiation.

Authors:  A Danielsson; E Karlsson; U Delle; K Helou; C Mercke
Journal:  J Cancer Res Clin Oncol       Date:  2005-03-18       Impact factor: 4.553

4.  The biological impact of the human master regulator p53 can be altered by mutations that change the spectrum and expression of its target genes.

Authors:  Daniel Menendez; Alberto Inga; Michael A Resnick
Journal:  Mol Cell Biol       Date:  2006-03       Impact factor: 4.272

5.  Cytokines inhibit p53-mediated apoptosis but not p53-mediated G1 arrest.

Authors:  Y Lin; S Benchimol
Journal:  Mol Cell Biol       Date:  1995-11       Impact factor: 4.272

6.  Expression of p53 and bcl-2 and response to preoperative chemotherapy and radiotherapy for locally advanced squamous cell carcinoma of the oesophagus.

Authors:  F Puglisi; C Di Loreto; R Panizzo; C Avellini; S Fongione; V Cacitti; C A Beltrami
Journal:  J Clin Pathol       Date:  1996-06       Impact factor: 3.411

7.  Long-term survivors of glioblastoma multiforme: clinical and molecular characteristics.

Authors:  M Morita; M K Rosenblum; M H Bilsky; R A Fraser; M R Rosenfeld
Journal:  J Neurooncol       Date:  1996-03       Impact factor: 4.130

8.  Foxp3 expression in p53-dependent DNA damage responses.

Authors:  Da-Jung Jung; Dong-Hoon Jin; Seung-Woo Hong; Jee-Eun Kim; Jae-Sik Shin; Daejin Kim; Byung-Joo Cho; Young-Il Hwang; Jae-Seung Kang; Wang-Jae Lee
Journal:  J Biol Chem       Date:  2010-01-14       Impact factor: 5.157

9.  Predictive value of p53, Bcl2 and bax in the radiotherapy of head and neck cancer.

Authors:  O Csuka; E Remenár; K Koronczay; Z Doleschall; G Németh
Journal:  Pathol Oncol Res       Date:  1997-09       Impact factor: 3.201

10.  Role of p53 mutation in the effect of boron neutron capture therapy on oral squamous cell carcinoma.

Authors:  Yusei Fujita; Itsuro Kato; Soichi Iwai; Koji Ono; Minoru Suzuki; Yoshinori Sakurai; Ken Ohnishi; Takeo Ohnishi; Yoshiaki Yura
Journal:  Radiat Oncol       Date:  2009-12-11       Impact factor: 3.481

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.